Evidence map›Paper›PMID 33822177›Full record

ArticleNeuro-oncology2021

Report of National Brain Tumor Society roundtable workshop on innovating brain tumor clinical trials: building on lessons learned from COVID-19 experience.

Eudocia Q Lee, Wendy Selig, Clair Meehan, Jeffrey Bacha, Amy Barone, Erik Bloomquist, Susan M Chang, John F de Groot, Evanthia Galanis, Islam Hassan and 13 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Sample-size determination for decentralized clinical trials.International journal of epidemiology · 2025
    Article
  3. Article
  4. How has the COVID-19 pandemic impacted clinical care and research in Neuro-Oncology?Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia · 2022
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 15 institutions in 2 countries.

Eudocia Q LeeCenter for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.ORCID 0000-0003-3355-5179
Wendy SeligWSCollaborative, McLean, Virginia, USA.
Clair MeehanNational Brain Tumor Society, Newton, Massachusetts, USA.
Jeffrey BachaEdison Oncology Holding Corp., Menlo Park, California, USA.
Amy BaroneOffice of Hematology and Oncology Products at the Food and Drug Administration, Silver Spring, Maryland, USA.
Erik BloomquistOffice of Biostatistics, Center for Drug Evaluation and Research at the Food and Drug Administration, Silver Spring, Maryland, USA.
Susan M ChangDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.
John F de GrootDepartment of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Evanthia GalanisDivision of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0001-8014-786X
Islam HassanAgios Pharmaceuticals, Cambridge, Massachusetts, USA.
Chitkala KalidasBayer Pharmaceuticals, Hillsborough, New Jersey, USA.
Mustafa KhasrawPreston Robert Tisch Brain Tumor Center at Duke, Departments of Neurosurgery, Duke University Medical Center, Durham, North Carolina, USA.ORCID 0000-0003-3249-9849
Joseph C KvedarDepartment of Dermatology at Massachusetts General Hospital, Boston, Massachusetts, USA.
Andrew B LassmanDepartment of Neurology and Herbert Irving Comprehensive Cancer Center, New-York Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, USA.
Vinay PuduvalliDepartment of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Solmaz SahebjamDepartment of Neuro-Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
Lee H SchwammDepartment of Neurology at Massachusetts General Hospital, Boston, Massachusetts, USA.
Sharon TamirKaryopharm Therapeutics, Inc., Newton, Massachusetts, USA.
Mary WelchDepartment of Neurology and Herbert Irving Comprehensive Cancer Center, New-York Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, USA.
W K Alfred YungDepartment of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Gelareh ZadehMacFeeters-Hamilton Center for Neuro-Oncology, Princess Margaret Cancer Center, Toronto, Ontario, Canada.ORCID 0000-0002-6637-4502
David AronsNational Brain Tumor Society, Newton, Massachusetts, USA.
Patrick Y WenCenter for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
The University of Texas MD Anderson Cancer Center · USCenter for Neuro-Oncology · USMassachusetts General Hospital · USNational Brain Tumor Society · USNewYork–Presbyterian Hospital · USAgios Pharmaceuticals (United States) · USBayer (United States) · USCenter for Drug Evaluation and Research · USDuke Medical Center · USKaryopharm Therapeutics (United States) · USMayo Clinic · USMoffitt Cancer Center · USPrincess Margaret Cancer Centre · CAUnited States Food and Drug Administration · USUniversity of California, San Francisco · US

Funding

Women's Cancer Research ProgramP30CA014236 · NCI · DUKE UNIVERSITY · PI DONNA NIEDZWIECKI · 1985 to 2026
$174.8M
NCI NIH HHS P30 CA014236
6 · The paper itself

Abstract

On July 24, 2020, a workshop sponsored by the National Brain Tumor Society was held on innovating brain tumor clinical trials based on lessons learned from the COVID-19 experience. Various stakeholders from the brain tumor community participated including the US Food and Drug Administration (FDA), academic and community clinicians, researchers, industry, clinical research organizations, patients and patient advocates, and representatives from the Society for Neuro-Oncology and the National Cancer Institute. This report summarizes the workshop and proposes ways to incorporate lessons learned from COVID-19 to brain tumor clinical trials including the increased use of telemedicine and decentralized trial models as opportunities for practical innovation with potential long-term impact on clinical trial design and implementation.

Indexed as

Brain NeoplasmsCOVID-19HumansNational Cancer Institute (U.S.)SARS-CoV-2United StatesUnited States Food and Drug Administrationclinical trialsCOVID-19decentralizationtelemedicine

Identifiers

PMID33822177
PMCPMC8083574
OpenAlexW3143439380

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.